"How long do peptides take to work" gets a vague answer online because it is asked as though peptides were one drug. They are not, and neither is "work": for one peptide it means an effect within the hour, for another a scan result after half a year, for another a weight change measured after more than a year. The honest way to answer is per compound, from the one kind of source that fixes both the endpoint and the clock — the trial, as summarised on the product's FDA label. This page does that for the approved peptides that have labels, and says plainly where there is nothing to report. It describes what trials measured; it does not suggest what anyone should expect or do. How the time a peptide stays in the body relates to all this is on our peptide half-life page.
The timelines on the labels
| Peptide (brand) | What "working" was measured as | When | Source |
|---|---|---|---|
| Bremelanotide (Vyleesi) | Sexual desire and related distress scores | Used ≥45 minutes before activity; scores assessed over 24 weeks | Vyleesi label, 2025-11-13 |
| Teriparatide (Forteo) | Lumbar spine bone mineral density; fractures | Density gains significant at 3 months; fracture trial median exposure 19 months | Forteo label, Lilly, 2026-08-03 |
| Abaloparatide (Tymlos) | Bone density; new vertebral fractures | Density primary endpoint at 12 months (Study 019); fracture reduction at 18 months | Tymlos label, 2026-08-11 |
| Setmelanotide (Imcivree) | BMI and hunger in rare genetic obesity | Significant BMI difference over a 14-week placebo period | Imcivree label, 2026-04-01 |
| Tesamorelin (Egrifta) | Visceral abdominal fat by CT | Primary endpoint at 26 weeks | Egrifta WR label, 2026-07-29 |
| Semaglutide 2.4 mg (Wegovy) | Percent body-weight change | Primary endpoint at 68 weeks | Wegovy label |
| Tirzepatide (Zepbound) | Percent body-weight change | Primary endpoint at 72 weeks | Zepbound label, Lilly, 2026-08-28 |
| Afamelanotide (Scenesse) | Pain-free hours in direct sunlight | Totals over 180 and 270 days; implant every 2 months | Scenesse label, 2026-05-11 |
Three things stand out when the rows are laid side by side. The spread runs from 45 minutes to 72 weeks — a factor of about 16,000. The endpoint dictates the clock: a peptide whose effect is on a signal in the brain (bremelanotide, a melanocortin agonist) is timed in minutes, one whose effect is on a slow tissue (bone, fat) in months. And a trial's endpoint week is the week the sponsor chose to measure, not the week the effect began — Forteo's label is one of the few that says when a difference first appeared, and it was well before the trial's end.
What a timeline on a label actually means
Each figure above is a difference from placebo at a pre-set time, in a specific population, at the labelled dose. That has three consequences worth stating.
It includes the time taken to reach the dose. Wegovy's and Zepbound's trials stepped the dose up over the first months, so the full labelled dose was reached around weeks 16–20 and the 68- and 72-week results include that climb. Our semaglutide and tirzepatide dosage pages set out the labelled escalation.
It is the average, not an individual timetable. The labels' figures chart mean change, and the spread around the mean is wide; some participants in every active arm changed little.
It says nothing about permanence unless the trial tested withdrawal. Two labels here did. In tesamorelin's extension phase, people who had taken it for 26 weeks were re-randomised: those switched to placebo regained visceral fat, +22% and +16% in the two studies over the next 26 weeks, while those who stayed on it held their loss (0% and −5%). Imcivree's label reports that patients who had lost at least 5 kg regained weight when treatment was withdrawn. The time a peptide takes to work and the time its effect outlasts it are different questions.
Research peptides: the absence is the answer
For the compounds most searched with this question — BPC-157, TB-500, ipamorelin, CJC-1295, epitalon, pinealon — there is no label and, in most cases, no human trial with a timed endpoint.
- BPC-157: FDA's 2026 review found five small human studies, about 80 people, none by subcutaneous injection and none longer than two weeks; none was designed to show when an effect starts. Details on our BPC-157 side-effects page.
- TB-500: FDA found no human study at all (our TB-500 record).
- Pinealon: no ClinicalTrials.gov record; the human reports are small Russian-language studies without a published time course (our pinealon page).
- Ipamorelin: the registered trials were in post-operative bowel recovery, a different endpoint from the uses it is marketed for (see ipamorelin vs sermorelin).
The timelines that circulate for these compounds — "pain relief in days", "tendon results in four to six weeks" — therefore come from vendor pages, clinic pages and personal reports. They may describe real experiences, but they cannot separate a peptide's effect from natural healing, from other changes made at the same time, or from expectation. The placebo arms in the labelled trials above show why that matters: in several, the placebo group also improved, and the label figure is only the difference.
Why the same question has no single answer
Put simply, "how long" depends on three things the trials hold fixed and online answers do not: which peptide (and, as our price survey shows, a vial's name does not always settle that), which outcome (a sensation, a lab value, a scan, a weight), and compared with what (placebo, or the person's own memory of before). Where all three are fixed, the labels give numbers; where they are not, there is nothing to report yet. Anyone deciding on a treatment, or judging whether one is working, should take the question to the prescribing clinician, who can set it against the trial the label describes.
Sources and dates
- Prescribing information via DailyMed / openFDA, read 2026-09-26: Vyleesi (Cosette, effective 2025-11-13); Forteo (Eli Lilly, 2026-08-03); Tymlos (Radius Health, 2026-08-11); Imcivree (Rhythm, 2026-04-01); Egrifta WR (Theratechnologies, 2026-07-29) — clinical studies sections incl. Tables 2 and 4; Wegovy (Novo Nordisk, DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b); Zepbound (Eli Lilly, 2026-08-28); Scenesse (Clinuvel, 2026-05-11).
- FDA. PCAC briefing documents for BPC-157 (fda.gov/media/193343) and TB-500 (fda.gov/media/193349), July 2026.
- ClinicalTrials.gov search for pinealon, 2026-09-26: no records.